Jun 17, 2020
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
Jun 12, 2020
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
May 14, 2020
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress
May 07, 2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
May 07, 2020
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
Nov 21, 2019
Global Hematological Malignancies Testing Market to Reach $4.60 Billion by 2025
Nov 15, 2019
Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
Oct 01, 2019
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
Jun 19, 2019
Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms
Jun 17, 2019
Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress
Jun 17, 2019
Data Presented At 24 Congress of the European Hematology Association Demonstrates Clinical Safety, Early Efficacy of Imago BioSciences' IMG-7289 in Myelofibrosis Patients
Apr 25, 2019
Health Union Survey Reveals Half of Blood Cancer Cases Detected from Symptoms, Other Half Incidental
Feb 21, 2019
PharmaEssentia and AOP Orphan Receive EU Approval of Besremi(TM) (Ropeginterferon Alfa-2b) for Treatment of Polycythemia Vera (PV) in EU
Feb 01, 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Dec 17, 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Dec 05, 2018
PharmaEssentia Updates Progress of Ropeginterferon Alfa-2b Clinical Program
Nov 12, 2018
Myeloproliferative Disorders Drugs Market Worth $9.26 Billion by 2023: Grand View Research, Inc.
Oct 04, 2018
Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"
Oct 01, 2018
CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
Jul 18, 2018
CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA